•
Dec 31, 2024
Sera Prognostics Q4 2024 Earnings Report
Sera Prognostics reported its Q4 2024 financial results, showing lower revenue and higher operating expenses compared to the prior year.
Key Takeaways
Sera Prognostics experienced a decline in revenue for Q4 2024 and continued investments in commercialization and research, resulting in a higher net loss. Despite this, the company raised additional funds to support its operations and future growth.
Q4 2024 revenue was $24,000, down from $41,000 in Q4 2023.
Net loss for the quarter was $8.58 million, compared to $7.93 million in the prior year.
Operating expenses increased to $9.45 million in Q4 2024.
Cash, cash equivalents, and marketable securities totaled $68.2 million at year-end 2024.
Sera Prognostics
Sera Prognostics
Forward Guidance
Sera Prognostics plans to expand commercial efforts in the US and prepare for European expansion, with a focus on driving adoption of its PreTRM test.
Positive Outlook
- PRIME study showed strong clinical outcomes.
- Raised $57.5 million in February 2025.
- Cash runway extended through 2028.
- Planned expansion in selected US geographies.
- Ongoing preparations for potential FDA submission.
Challenges Ahead
- Revenue remains low compared to expenses.
- Continued net losses impacting profitability.
- Increased operating expenses year-over-year.
- Dependency on successful commercial adoption.
- Regulatory approval process still pending for broader adoption.